Detecção de marcadores de resistência a múltiplas drogas na pele de cães com infecção natural por Leishmania (Leishmania) infantum chagasi (Cunha e Chagas, 1937) Shaw, 2002, submetidos a diferentes protocolos de tratamento

• Ano de defesa: 2014
• Autor(a) principal: Calado, Andréa Maria Campos [UNESP]
• Tipo de documento: Tese
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Estadual Paulista (Unesp)
• Palavras-chave em Português: Cão; Leishmaniose visceral; Glicoproteinas; Imuno-histoquímica; Marcadores biologicos; Glycoproteins
• Link de acesso: http://hdl.handle.net/11449/121885

The treatment of dogs with visceral leishmaniasis in Brazil has generated controversial debate among various segments of health professionals. On one side, veterinarians pressured by dog owners want to have the right to decide between treatment and euthanasia of their animals. On the other hand, the Ministry of Health and the Ministry of Agriculture, Livestock, and Supply (MAPA) are opposed to treatment because of the risk of creating strains of the parasite resistant to drugs that are also used for human patients. Scientific arguments that can support this controversy should be explored. One possibility for assessing the development of drug resistance can be achieved through research of the expression of Pglycoprotein (P-gp) and multidrug resistance-associated protein (MRP1). These proteins, which are responsible for the MDR phenotype (multiple drug resistance), act as efflux pumps which expel xenobiotics from cells. Using immunohistochemistry, the reactivity of P-gp (clone C494) and MRP1 (clone ABCC1) in the skin of 11 dogs naturally infected by Leishmania (L.) infantum chagasi was analyzed before and after undergoing two treatment protocols: Allopurinol and inactivated vaccine (n=4) and Allopurinol, inactivated vaccine, and domperidone (n=7). Quantification of Leishmania amastigotes in the skin was also achieved via immunohistochemistry. All of the animals after 3 and 6 months of treatment had clinical improvement and tested negative for amastigote forms of the parasite. Yet, the skin of dogs positive for CVL (canine visceral leishmaniasis) expressed P-gp and MRP1 before and after treatment, illustrating that P-gp and MRP1 were neither good markers for evaluating the therapeutic efficacy of CVL nor for predicting the possible states of drug resistance. However, an understanding of the participation of markers for multiple drug resistance in the skin of dogs under treatment for CVL can be of great importance for the development of an ...